Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

EHA Guidelines Workshop series

 

EHA has initiated a series of online workshops dedicated to guidelines (produced or endorsed by EHA) aimed at disseminating good practices and knowledge for diagnosis and treatment of hematologic diseases.

Read more

EHA Education & Mentoring Award

“Educating and mentoring are a brain to pick, an ear to listen, and a push in the right direction. ”

Through this award, EHA recognized excellent teachers and mentors at any stage of their career.

Read more

Jean Bernard Lifetime Achievement Award

The Jean Bernard Lifetime Achievement Award was established in 2008 to honor outstanding physicians and scientists for their lifetime contribution to the advancement of hematology.

Read more

ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models

November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.

Read more

5th Focus in Paediatric Haematology-Oncology

The course, which is particularly aimed at specialist trainees in pediatric haemato-oncology, continued the same ethos which inspired the first four courses: the importance of close interactions between the participants and the teaching faculty, a strong emphasis on real cases…

Read more

EHA-BMSH Balkan Hematology Tutorial

EHA is joining the Bulgarian Medical Society of Hematology (BMSH) to organize the EHA-BMSH Balkan Hematology Tutorial on Myeloproliferative disorders.

Read more